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Abstract 
Major depression is a highly complex disabling psychiatric disorder affecting millions of people 
worldwide. Despite the availability of several classes of antidepressants, a substantial 
percentage of patients are unresponsive to these medications. A better understanding of the 
neurobiology of depression and the mechanisms underlying antidepressant response is thus 
critically needed. We previously reported that mice lacking CREB-regulated transcription 
coactivator 1 (CRTC1) exhibit a depressive-like phenotype and a blunted antidepressant 
response to the selective serotonin reuptake inhibitor fluoxetine. In this study, we similarly 
show that Crtc1‒/‒ mice are resistant to the antidepressant effect of chronic desipramine in a 
behavioral despair paradigm. Supporting the blunted response to this tricyclic antidepressant, 
we found that desipramine does not significantly increase the expression of Bdnf and Nr4a1-3 
in the hippocampus and prefrontal cortex of Crtc1‒/‒ mice. Epigenetic regulation of 
neuroplasticity gene expression has been associated with depression and antidepressant 
response, and histone deacetylase (HDAC) inhibitors have been shown to have antidepressant-
like properties. Here, we show that unlike conventional antidepressants, chronic systemic 
administration of the HDAC inhibitor SAHA partially rescues the depressive-like behavior of 
Crtc1‒/‒ mice. This behavioral effect is accompanied by an increased expression of Bdnf, but not 
Nr4a1-3, in the prefrontal cortex of these mice, suggesting that this epigenetic intervention 
restores the expression of a subset of genes by acting downstream of CRTC1. These findings 
suggest that CRTC1 alterations may be associated with treatment-resistant depression, and 
support the interesting possibility that targeting HDACs may be a useful therapeutic strategy in 
antidepressant development. 
Keywords: mood disorders; antidepressants; animal model of depression; CREB coactivator; 
BDNF; HDAC inhibitor; SAHA; epigenetics. 
Chemical compounds studied in this article 
Desipramine hydrochloride (PubChem CID: 65327); Vorinostat (PubChem CID: 5311) 
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1. Introduction 
Mood disorders (including major depressive disorders and bipolar disorders) are a major cause 
of disability worldwide, with an estimated lifetime prevalence of 16% (Kessler et al., 2005). 
Although the underlying etiological mechanisms are complex and still unclear, studies over the 
past decades have highlighted the importance of the transcription factor cyclic adenosine 
monophosphate (cAMP) response element-binding protein (CREB) and one of its target genes 
brain-derived neurotrophic factor (Bdnf) (Blendy, 2006; Krishnan and Nestler, 2008; 
Martinowich et al., 2007). CREB is a pleiotropic transcription factor involved, in particular, in 
neuronal growth and survival, neurogenesis, synaptic plasticity and long-term memory (Blendy, 
2006; Carlezon et al., 2005; Lonze and Ginty, 2002). BDNF is also implicated in these processes, 
partly through the induction of its expression by CREB (Martinowich and Lu, 2008; Martinowich 
et al., 2007). CREB and BDNF have both been involved in depression and antidepressant 
treatment. Indeed, overexpression of CREB and BDNF in the hippocampus (HIP) results in 
antidepressant effects (Chen et al., 2001; Shirayama et al., 2002) and inversely, chronic stress 
reduces Bdnf expression in the same structure (Smith et al., 1995). Of note, antidepressants 
such as fluoxetine and desipramine were also shown to upregulate Bdnf expression in the 
prefrontal cortex (PFC) and HIP of rodents in a CREB-dependent manner (Conti et al., 2002). 
CREB-regulated transcription coactivator 1 (CRTC1) is a potent CREB coactivator activated by 
cAMP and Ca2+ signaling that trigger its dephosphorylation and translocation to the nucleus, 
where it binds to CREB, helps to recruit CREB-binding protein (CBP) and RNA polymerase II, and 
thus activates CREB-dependent gene transcription ( Altarejos and Montminy, 2011; Ch'ng et al., 
2012; Conkright et al., 2003; Kovacs et al., 2007; Ravnskjaer et al., 2007; Screaton et al., 2004). 
CRTC1 is involved in activity-induced dendritic growth and late phase long-term potentiation (L-
LTP) (Kovacs et al., 2007; Li et al., 2009; Zhou et al., 2006). Moreover, Bdnf expression as well as 
BDNF-dependent dendritic growth require CRTC1 (Finsterwald et al., 2010; Kovacs et al., 2007; 
Zhou et al., 2006). Region-specific CRTC1’s activation is critical for activity-dependent 
immediate early genes regulation and long-term fear memory (Nonaka et al., 2014a; Sekeres et 
al., 2012). CRTC1-dependent transcription of Bdnf and orphan nuclear receptors 4a (Nr4a) is 
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also involved in cognitive impairments related to Alzheimer’s disease (Parra-Damas et al., 
2014). 
To further investigate the role of CRTC1 in the brain, we generated a CRTC1-deficient mouse 
line that exhibits several endophenotypes related to mood disorders and a blunted response to 
the antidepressant fluoxetine in behavioral despair-related paradigms (Breuillaud et al., 2009; 
Breuillaud et al., 2012). At the molecular level, Crtc1‒/‒ mice have a decreased HIP and PFC 
expression of several CREB-regulated neuroplasticity genes, including notably Bdnf and Nr4a1-3 
(Breuillaud et al., 2012). Altogether, this suggests that CRTC1, as a key regulator of 
neuroplasticity-related genes, is critical for mood regulation and antidepressant response. 
However, the direct or indirect mechanisms linking CRTC1’s deficiency and behavioral 
consequences are still unclear. As CRTC1 promotes CBP recruitment, which has an intrinsic 
histone acetyltransferase (HAT) activity, these mechanisms might include CRTC1-related 
epigenetic gene regulation. Noteworthily, epigenetic mechanisms have been widely associated 
with depressive disorders and with CREB and Bdnf regulation in the frame of stress and 
antidepressant response (Lin et al., 2012; Tsankova et al., 2007; Tsankova et al., 2006; Vecsey et 
al., 2007; Vialou et al., 2013).  
In this study, we were interested in further investigating the involvement of CRTC1 in 
antidepressant response and the underlying molecular mechanisms. We first tested the effects 
of chronic desipramine on the behavior of Crtc1‒/‒ mice, which revealed a blunted behavioral 
response to this antidepressant. We also observed that desipramine failed to induce Bdnf and 
Nr4a1-3 expression in the HIP and PFC of Crtc1‒/‒ mice. By acting at the epigenetic levels and 
treating the animals with a HDAC inhibitor, we were able to partially rescue the depressive-like 
behavior of Crtc1‒/‒ mice. This was paralleled by an increased expression of Bdnf, but not 
Nr4a1-3, in the PFC of these animals. 
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2. Materials and Methods 
2.1. Animals 
Crtc1‒/‒ mice and wild-type (WT) littermates were generated and genotyped as previously 
described (Breuillaud et al., 2009). Mice were housed under a 12-h light-dark cycle with ad 
libitum access to water and standard rodent chow diet. Male mice were weaned at 21 days and 
group-housed until being isolated at 5 weeks of age in order to avoid wounding of cage mates 
by aggressive Crtc1‒/‒ males (Breuillaud et al., 2012). All animal experiments were conducted in 
accordance with the Swiss Federal Veterinary Office’s guidelines and were approved by the 
Cantonal Veterinary Service. Behavioral procedures began when mice reached the age of 8 
weeks.  
 
2.2. Drugs and treatment 
Desipramine hydrochloride was purchased from Sigma (St-Louis, MO, USA). Mice received 
desipramine in the drinking water at a concentration of 100 mg/l, which corresponds to 
approximately 20 mg/kg of body weight/day. Desipramine solution was changed every week 
and concentration was adjusted depending on the weight gain and average water consumption 
of the mice. Suberoylanilide hydroxamic acid (SAHA, also known as vorinostat) was purchased 
from Selleck Chemicals (Houston, TX, USA). Mice received SAHA through daily intra-peritoneal 
injections. SAHA was first dissolved in DMSO at a dose of 50 mg/ml. This stock solution was 
diluted 1:10 every day in saline solution (final concentration: 5 mg/ml) prior to injections at a 
dose of 25 mg/kg of body weight. Vehicle groups were injected with a solution of 10% DMSO in 
saline. 
 
2.3. Repeated open-space forced swim procedure (OSFS) 
The repeated OSFS procedure was performed as previously described (Breuillaud et al., 2012; 
Stone and Lin, 2011). Briefly, swimming was carried out in rat tub cages (24x43x23 cm) filled 
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with ~14 cm of lukewarm tap water (34±0.5°C) and colored with ~10 ml of milk. Mice 
undertook individual daily swim of 15 minutes during 4 consecutive days (Days -4 to -1). On day 
0, desipramine or SAHA treatment started. Swimming sessions were repeated at 3 or 4 days of 
intervals during 3 weeks (Days 2, 5, 9, 12, 16, 19, 23) under continuous treatment (Fig. 1A). 
Water was changed after 4 mice had swum, in order to maintain water temperature. Swimming 
sessions were videotaped from above. Time spent immobile (drifting with no observable 
movement of limbs or tail) was manually recorded. 
 
2.4. Novelty-induced hypophagia (NIH) 
NIH procedure started on day 24, one day after the last swimming session (Fig. 1A). Mice were 
trained to drink sweetened condensed milk (1:3, condensed milk: water) for two consecutive 
days (day 24 and 25), 2x1h each day. Milk was presented in homemade drinking tubes made of 
10 ml conical tubes (Sarsedt) with a hole at the bottom closed by a glass bead (5 mm diameter) 
to make a sipper. Tubes were placed through wire cage lids. On the third day (day 26), mice 
were tested in homecage conditions (light intensity: ~27 lux). Mice were videotaped during 15 
min from the side and latency to drink was measured. On the fourth day (day 27), mice were 
placed in a novel cage without bedding, under bright light (~1200 lux), and the same 
measurements were made. The cage was cleaned with water and 70% ethanol between each 
mouse and before the first mouse. 
 
2.5. Brain microdissection and micropunching 
On day 28, one day after the end of the NIH procedure, all mice were sacrificed by cervical 
dislocation and decapitation. The brain was rapidly placed in a stainless steel adult mouse brain 
slicer matrix with 1 mm coronal section slice intervals. Six coronal slices were made from the 
second frontal slice channel of the matrix. Brain slices were placed on microscope slides and 
immediately frozen in dry ice, and then stored at -80°C. Medial PFC and dorsal HIP were 
collected with a micropunch (ø 1 mm, Stoelting, Wood Dale, IL, USA) in corresponding brain 
slices. PFC and HIP samples were kept at -80°C. 
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2.6. Gene expression analysis 
Total RNA was extracted and purified from the PFC and HIP micropunches, using the RNAeasy 
Plus Minikit (Qiagen, Venlo, Netherland) according to the manufacturer’s instructions. RNA 
concentrations were measured by UV spectrophotometry with a NanoDrop Lite (Thermo 
Scientific, Wilmington, DE, USA). cDNA was prepared in a 50 μl reaction by reverse 
transcription, using 100 ng of RNA with Taqman Reagents and random hexamers (Applied 
Biosystems, Foster City, CA, USA). 0.8 μl of cDNA was amplified on a 96-well plate using the 
SYBR Green PCR Master Mix (Applied Biosystem). Amplification was performed with an 
ABIPRISM 7500 real-time PCR system (Applied Biosystem). The program was 2 min at 50°C, 10 
min at 95°C, followed by 45 cycles of 15 s at 95°C and 1 min at 60°C. Relative gene expression 
was quantified using the comparative ΔΔ Ct method and normalized with -actin transcript 
levels.  
The following primers were used, at a concentration of 250 nM: -actin forward 5’-
GCTTCTTTGCAGCTCCTTCGT-3’, -actin reverse 5’-ATATCGTCATCCATGGCGAAC-3’, Crtc1 forward 
5’-CAGGACTTGGGCCTGGAA-3’, Crtc1 reverse 5’-AGACAGACAAGACCCTTTCTAAGCA-3’; Bdnf 
forward 5’-AAAACCATAAGGACGC GGACTT-3’, Bdnf reverse 5’-GAGGCTCCAAAGGCACTTGA-3’; 
Bdnf exIV forward 5’-GTAAG AGTCTAGAACCTTGGGGACC-3’, Bdnf exIV reverse 5’-
GGATGGTCATCACTCTTCTCACCT-3’; Nr4a1 forward 5’-AAAATCCCTGGCTTCATTGAG-3’, Nr4a1 
reverse 5’-TTAGA TCGGTATGCCAGGCG-3’; Nr4a2 forward 5’-CGGTTTCAGAAGTGCCTAGC-3’, 
Nr4a2 reverse 5’-TTGCCTGGAACCTGGAATAG-3’; Nr4a3 forward 5’-
TGGCTCGACTCCATTAAAGAC-3’, Nr4a3 reverse 5’-TGCATAGCTCCTCCACTCTCT-3’; Hdac1 
forward 5’-TTCCAACATGACCAACCAGA-3’, Hdac1 reverse 5’-GGCAGCATCCTCAAGTTCTC-3’, 
Hdac2 forward 5’-GGGACAGGCTTGGTTGTTTC-3’, Hdac2 reverse 5’-GAGCATCAGCAATGGCAAGT-
3’, Hdac3 forward 5’-AGAGAGGTCCCGAGGAGAAC-3’, Hdac3 reverse 5’-
ACTCTTGGGGACACAGCATC-3’, Hdac4 forward 5’-CAATCCCACAGTCTCCGTGT-3’, Hdac4 reverse 
5’-CAGCACCCCACTAAGGTTCA-3’, Hdac5 forward 5’-TGTCACCGCCAGATGTTTTG-3’, Hdac5 
reverse 5’-TGAGCAGAGCCGAGACACAG-3’, Hdac7 forward 5’-GGTGGACCCCCTTTCAGAAG-3’, 
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Hdac7 reverse 5’-TGGGTAGCCAGGAGTCTGGA-3’, Hdac9 forward 5’-
GCGAGACACAGATGCTCAGAC-3’, Hdac9 reverse 5’-TGGGTTTTCCTTCCATTGCT-3’. 
 
2.7. Effects of SAHA on histone acetylation 
Mice were weaned and housed according to 2.1 . At the age of 8 weeks, Crtc1‒/‒ mice and WT 
littermates received a single injection of either SAHA or vehicle as in 2.2. Animals were 
sacrificed 2h after the injection, with a similar procedure as in 2.5. Histone acetylation was 
measured by Western blotting.  
 
2.8. Western Blot 
Histones were extracted from HIP and PFC micropunches using the Histone Purification Minikit 
(Active Motif, Carlsbad, CA, USA) according to the manufacturer’s instructions. Samples with 
poor histone yield were excluded. 1 μg of extracted histones were diluted 1:1 with sample 
buffer [65.8 mM Tris-HCl pH 6.8, 26.3% glycerol, 2.1% SDS, 100mM DTT, 0.01% bromophenol 
blue], separated on a 15% SDS-polyacrylamide gel, and proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes with a Transblot Turbo Transfer System (BioRad, 
Hercules, CA, USA). Blots were blocked for 1 hour at room temperature (RT) in TBST [10 mM 
Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% Tween-20], supplemented with 5% skim milk powder. 
Blots were subsequently incubated with a primary antibody in TBST plus 5% bovine serum 
albumin (BSA) overnight at 4°C. Finally, PVDF membranes were incubated for 1 hour at RT with 
horseradish peroxidase (HRP)-conjugated secondary antibodies in TBST plus 5% skim milk 
powder, and developed using a Pierce ECL Western chemiluminescence detection kit (Thermo 
Scientific). The following antibodies and dilutions were used: rabbit α-Acetyl-Histone H3, 1:2500 
(EMD Millipore, Temecula, CA, USA), rabbit α-Histone H3, 1:2000 (Abcam, Cambridge, UK), 
rabbit α-Acetyl-Histone H4, 1:2000 (EMD Millipore), rabbit α-Histone H4, 1:2000 ( EMD 
Millipore), donkey HRP-α-rabbit 1:2000 (GE Healthcare, Little Chalfont, UK). Quantification of 
band intensity was performed with Image J software (National Institute of Health, Bethesda, 
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MD, USA). Acetyl-H3 and acetyl-H4 band intensities were normalized with total H3 and H4 
signals, respectively. 
 
2.9. Statistical analyses 
Statistical analyses were performed using the Statistica 8.0 Software (StatSoft Inc., Tulsa, OK, 
USA). All data are presented as mean ± SEM. P-values of p < 0.05 were considered as 
statistically significant. A Shapiro-Wilk test was first performed to assess data normality. All 
results were found to follow normal distribution; therefore parametric tests could be used. For 
both behavioral and molecular analyses, a two-way ANOVA was performed to assess statistical 
differences for two factors (genotype and treatment). A Fisher LSD post-hoc test was carried 
out afterwards. For analyses of the OSFS data, a two-way ANOVA with repeated measures was 
performed as immobility time was repeatedly measured. A Fisher LSD post-hoc test was carried 
out afterwards.  
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3. Results 
3.1. Crtc1‒/‒ mice have a blunted behavioral response to chronic desipramine treatment 
Behavioral effects of desipramine were first assessed in the open-space forced swim (OSFS) 
model of depression (Fig. 1A and 1B). This protocol induces depressive-like symptoms that are 
reversed by chronic, but not acute, antidepressant treatments, and thus it has better face and 
construct validities than the conventional forced swim test (Breuillaud et al., 2012; Stone and 
Lin, 2011; Stone et al., 2008). All animals presented increased immobility time after the four 
days of consecutive swimming with a significant effect of time (F(1,37)=36.1, p<0.001) and 
genotype (F(1,111)=13.7, p<0.001). Crtc1
‒/‒ mice had higher immobility time than WT mice during 
the last two sessions of the pre-test period (day -2 and -1) (p<0.001 for both days). This 
genotype effect remained significant after the beginning of the desipramine treatment 
(F(1,35)=71.34, p<0.001), indicating that Crtc1
‒/‒ mice had higher immobility time that WT mice 
during the whole procedure. WT mice progressively responded to desipramine, as their 
immobility time significantly decreased over time. As compared to their own immobility time 
on day 2 of treatment, the effect of desipramine became significant starting from day 9 
(p=0.029 on day 9, p=0.003 on day 12, p<0.001 on days 16, 19 and 23, vs. day 2). Their 
immobility time was also lower than untreated WT mice, starting from day 9 as well (p=0.032 
on day 9, p=0.032 on day 12, p=0.023 on day 12, p=0.016 on day 19, p=0.009 on day 23, vs. WT 
untreated). Desipramine had no effect on the depressive-like behavior of Crtc1‒/‒ mice, 
indicating that these mice were resistant to desipramine in this paradigm. At the end of the 
procedure, mice were then tested in the novelty-induced hypophagia (NIH) test, a depression- 
and anxiety-related paradigm sensitive to chronic antidepressant treatment (Dulawa and Hen, 
2005) (Fig. 1A and 1C). In homecage conditions, genotype or treatment had no effect on the 
latency to consume condensed milk, whereas a significant effect of desipramine was found in 
the novel environment (F(1,30)=6.52, p=0.016). Desipramine significantly decreased the latency 
of Crtc1‒/‒ mice (p=0.005, vs. untreated Crtc1‒/‒ mice), thus showing that these mice responded 
positively to desipramine in this paradigm. Comparably to their response to fluoxetine 
(Breuillaud et al., 2012), Crtc1‒/‒ mice show a blunted response to chronic desipramine in the 
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OSFS test and a reduced latency to drink sweetened milk in the anxiogenic environment of the 
NIH, which suggest a differential involvement of CRTC1 in the behavioral response to 
antidepressants. 
 
3.2. Desipramine fails to induce expression of neuroplasticity-related genes in Crtc1‒/‒ mice 
In order to investigate the molecular mechanisms underlying the blunted behavioral response 
of Crtc1‒/‒ mice to desipramine, gene expression analysis was performed in the HIP and PFC of 
these animals (Fig. 2). Crtc1‒/‒ mice have a reduced expression of several neuroplasticity-
related genes in these brain regions involved in depressive disorders (Breuillaud et al., 2012). 
We were first interested in assessing a possible effect of desipramine on Crtc1 expression in WT 
mice (Fig. 2A). Desipramine upregulated Crtc1 mRNA in the PFC of WT mice (t=-2.35, df=12, 
p=0.037, vs. WT untreated), which further suggests a role for CRTC1 in antidepressant 
response. Total Bdnf expression was then measured in WT and Crtc1‒/‒ mice (Fig. 2B). In the 
HIP, genotype had a significant effect on Bdnf expression (F(1,27)=4.53, p=0.042), unlike 
desipramine that had no effect. Indeed, Crtc1‒/‒ mice had lower levels of Bdnf mRNA (p=0.044, 
vs. WT untreated) as previously observed in these animals (Breuillaud et al., 2012). In the PFC, a 
significant effect of treatment was found (F(1,22)=9.08, p=0.006), which revealed that 
desipramine significantly induced Bdnf expression in WT mice (p=0.003, vs. WT untreated), but 
failed to do so in Crtc1‒/‒ mice. Promoter IV-driven Bdnf expression (BdnfIV) analysis showed a 
significant effect of treatment in the HIP (F(1,22)=13.46, p=0.001), as desipramine induced an 
increased expression of BdnfIV mRNA in WT mice (p=0.002 vs. WT untreated), but not in 
Crtc1‒/‒ mice (Fig. 2C). No significant effect of genotype or treatment was observed in the PFC. 
We were then interested in measuring Nr4a1-3 gene expression, as these orphan nuclear 
receptors are downregulated in Crtc1‒/‒ mice (Breuillaud et al., 2012). Furthermore, NR4A1-3 
have been shown to be involved in Bdnf regulation, in mood disorders and in neuroprotection 
(Schaffer et al., 2010; Volakakis et al., 2010; Volpicelli et al., 2007). Analysis of Nr4a1 expression 
(Fig. 2D) revealed a significant effect of genotype in the HIP (F(1,27)=6.71, p<0.015), showing 
that, independently of the treatment, Crtc1‒/‒ mice presented decreased levels of Nr4a1 
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(p=0.025 vs. WT untreated). In the PFC, genotype had a significant effect (F(1,26)=23.84, 
p<0.001). Desipramine significantly increased Nr4a1 expression in WT mice (p=0.026 vs. WT 
untreated), but not in Crtc1‒/‒ mice, which also presented decreased Nr4a1 levels (p=0.003 vs. 
WT untreated). Similar results were observed for Nr4a2 expression (Fig. 2E). A significant 
effects of genotype was observed in both structures (HIP: F(1,27)=22.79, p<0.001; PFC: 
F(1,27)=39.04, p<0.001), as Crtc1
‒/‒ mice presented lower levels of Nr4a2 expression (HIP: 
p=0.002; PFC: p<0.001, vs. WT untreated). Furthermore, desipramine induced Nr4a2 expression 
in the HIP and PFC of WT mice (HIP: p=0.035; PFC: p=0.008, vs. WT untreated). A significant 
genotype*treatment interaction was found in the PFC (F(1, 27)=5.12, p=0.031) as desipramine 
had no effect in Crtc1‒/‒ mice. Finally, no effect of genotype or treatment was observed for 
Nr4a3 in the HIP (Fig. 2F), whereas only a genotype effect was found in the PFC, (F(1,27)=27.59, 
p<0.001), as Crtc1‒/‒ mice presented decreased Nr4a3 expression (p<0.001, vs. WT untreated). 
Altogether, these data show that desipramine fails to induce the expression of Bdnf, Bdnf IV, 
Nr4a1 and Nr4a2 in the PFC and HIP of Crtc1‒/‒ mice, therefore possibly explaining their 
abnormal behavioral response to this antidepressant. 
 
3.3. SAHA partially rescues the depressive-like phenotype of Crtc1‒/‒ mice 
As CRTC1 is helping phosphorylated CREB to recruit the histone acetyltransferase CBP, we 
reasoned that HDAC inhibition might compensate for the possible deficit of CBP recruitment in 
Crtc1‒/‒ mice, and thus rescue the expression of neuroplasticity genes involved in mood 
regulation. Moreover, several lines of evidence both in humans and in animal models have 
suggested that pathological conditions may alter the expression of Hdac family members, 
mainly of class I and IIa (Covington et al., 2009; Gräff et al., 2012; Han et al., 2014; Morris and 
Monteggia, 2013; Tsankova et al., 2006; Uchida et al., 2011). Therefore, we first measured the 
expression of class I (Hdac1,2,3) and class IIa (Hdac4,5,7,9) members in the HIP and PFC of WT 
and Crtc1‒/‒ mice to determine whether mutant mice may present a possible altered epigenetic 
profile (Fig. 3A and 3B). We found that expression of most Hdac tested was globally unchanged 
in the HIP and PFC of Crtc1‒/‒ mice, except for Hdac9 that was slightly upregulated in the HIP of 
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mutant mice (t=-4.29, df=10, p=0.002, vs. WT mice) (Fig. 3A). However, this increased 
expression of Hdac9 in the HIP of Crtc1‒/‒ mice did not influence global acetylation of histone 
H3 and H4, as revealed by Western blot analysis (Fig. 3C-F). This suggested that the behavioral 
and molecular phenotypes of Crtc1‒/‒ mice did not result from a major alteration of Hdac 
expression and histone acetylation.  
HDAC inhibitors have been shown to have antidepressant effects in rodents and to regulate 
similar patterns of genes as antidepressants (Covington et al., 2009; Schroeder et al., 2007). 
SAHA is a hydroxamic acid compound that inhibits class I and II HDACs (Gräff and Tsai, 2013). 
Systemic administration of SAHA increases histone acetylation in the brain and has 
antidepressant effects in mice (Hockly et al., 2003; Uchida et al., 2011). Moreover, in primary 
neuronal cultures, SAHA induces a rapid increase in histone acetylation at Bdnf promoters I and 
IV, and an upregulation of Bdnf expression (Koppel and Timmusk, 2013). Therefore, SAHA was 
chosen to assess the behavioral response of WT and Crtc1‒/‒ mice to chronic HDAC inhibition. 
We first controlled that an intraperitoneal injection of SAHA indeed triggered an increase of 
histone acetylation in the brain of WT and Crtc1‒/‒ mice (Fig. 3C-F). Acetyl-H3 and Acetyl-H4 
signals were quantified and normalized over total H3 and total H4 signals. Analysis of histone 
H3 acetylation (Fig. 3C-D) showed a significant effect of SAHA in the HIP (F(1, 14)=11.17, p=0.004) 
and in the PFC (F(1,14),=13.86, p=0.002) of WT (HIP: p=0.014, PFC: p=0.003, vs. WT vehicle) and 
Crtc1‒/‒ mice (HIP: p=0.017, PFC: p=0.032, vs. Crtc1‒/‒ vehicle). Similarly, SAHA had a significant 
effect on H4 acetylation (Fig. 3E-F) in the HIP (F(1, 14)=9.28, p=0.008) and in the PFC (F(1,13)=13.97, 
p=0.001) of WT (PFC: p=0.003, vs. WT vehicle) and Crtc1‒/‒ mice (HIP: p=0.003, PFC: p=0.034, vs. 
Crtc1‒/‒ vehicle). 
Having shown that SAHA crosses the blood-brain barrier and increases histone acetylation in 
the brain, we then tested the behavioral response of WT and Crtc1‒/‒ mice to chronic SAHA 
treatment. Animals were first tested in the OSFS protocol (Fig. 4A and 4B). During the initial 
four consecutive days (from day -4 to -1), all groups showed an increase in their immobility 
time, with a significant interaction of time and genotype (F(3,96)=3.89, p=0.011), and Crtc1
‒/‒ 
mice progressively displayed increased immobility time as compared to WT mice (day -3: 
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p=0.02, day-2: p=0.001, day-4: p<0.001, vs. WT mice). After the beginning of SAHA treatment, a 
significant effect of genotype (F(1,30)=20.21, p<0.001) and a significant interaction of time and 
treatment (F(6,180)=6.23, p<0.001) were observed. SAHA-treated mice rapidly decreased their 
immobility time, as compared to their score at the beginning of the treatment (day 5: p=0.01, 
day 9: p=0.007, day 12-23: p<0.001, vs. themselves on day 2). Their immobility time was also 
significantly lower than vehicle-treated WT mice on the last three sessions (day 16: p=0.037, 
day 19: p=0.049, day 23: p=0.046, vs. WT Vehicle). Vehicle-treated Crtc1‒/‒ mice displayed 
higher immobility time than WT mice during the whole procedure (day 2-23: p<0.001, vs. WT 
Vehicle). Crtc1‒/‒ mice responded to SAHA, as they progressively decreased their immobility 
time (day 12: p=0.007, day 16: p=0.001, day 19: p=0.005, day 23: p=0.009, vs. themselves on 
day 2). Animals were then tested in the NIH paradigm (Fig. 4A and 4C). In the homecage 
conditions, there was no effect of genotype or treatment, whereas a significant effect of 
genotype was observed in the novel environment (F(1,26)=4.55, p=0.042), where SAHA decreased 
the latency of WT mice (p=0.039, vs. WT Vehicle). There was not however a significant effect of 
SAHA on Crtc1‒/‒ mice, although SAHA-treated mutant mice presented a trend to a decreased 
latency. Taken together, these results show that SAHA improves the phenotype of Crtc1‒/‒ 
mice, as it partially rescued their depressive-like behavior in the OSFS paradigm. 
 
3.4. SAHA partially restores normal gene expression in Crtc1‒/‒ mice 
Gene expression analysis of Crtc1, Bdnf, BdnfIV and Nr4a1-3 was performed in order to 
investigate the effects of chronic SAHA on these genes (Fig. 5). SAHA had no effect on Crtc1 
expression in the HIP and PFC of WT mice (Fig. 5A). A significant effect of genotype on total 
Bdnf expression (Fig. 5B) was seen in the HIP (F(1,26)=18.06, p<0.001), as Crtc1
‒/‒ mice 
surprisingly displayed higher Bdnf mRNA levels than WT mice (p=0.02, vs. WT Vehicle). In the 
PFC, a significant effect of treatment was observed (F(1,26)=8.52, p=0.007), as chronic SAHA 
increased Bdnf mRNA levels in Crtc1‒/‒ mice (p=0.009, vs. Crtc1‒/‒ Vehicle). Analysis of Bdnf 
promoter IV expression (Fig. 5C) did not reveal any effect of genotype or treatment in the HIP, 
whereas a significant genotype and treatment effect was observed in the PFC (genotype: 
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F(1,25)=4.82, p=0.037; treatment: F(1,25)=10.11, p=0.003), where Crtc1
‒/‒ mice displayed lower 
expression of BdnfIV (p=0.039, vs. WT Vehicle). SAHA treatment successfully restored BdnfIV 
levels in Crtc1‒/‒ mice (p=0.005, vs. Crtc1‒/‒ Vehicle). Measure of Nr4a1 mRNA expression (Fig. 
5D) showed a significant interaction of genotype and treatment (F(1,25)=9.58, p=0.004), as SAHA 
increased Nr4a1 expression in the HIP of WT mice (p=0.001, vs. WT Vehicle), but had no effect 
in Crtc1‒/‒ mice. In the PFC, a significant effect of genotype was observed (F(1,27)=15.57, 
p<0.001), as Crtc1‒/‒ mice showed lower levels of Nr4a1 (p=0.005, vs. WT Vehicle). SAHA had no 
effect on both genotypes in this structure. Similar effects of SAHA on Nr4a2 expression were 
observed in the HIP (Fig. 5E), where SAHA increased Nr4a2 levels in WT mice (p=0.001, vs. WT 
Vehicle), but had no effect in Crtc1‒/‒ mice. SAHA also increased Nr4a2 levels in the PFC of WT 
mice (p=0.013, vs. WT mice). A significant effect of genotype was also visible in the same 
structure (F(1,24)=14.12, p<0.001), as Crtc1
‒/‒ mice displayed decreased expression of Nr4a2 
(p=0.005, vs. WT Vehicle). Genotype or treatment had no effect on Nr4a3 mRNA levels in the 
HIP (Fig. 5F). In the PFC, a significant interaction of genotype and treatment (F(1,25)=4.54, 
p<0.042) was observed, as SAHA increased Nr4a3 expression in WT mice only (p=0.012, vs. WT 
Vehicle). 
Taken together, these results interestingly show that chronic SAHA treatment restored normal 
Bdnf and BdnfIV expression in the PFC of Crtc1‒/‒ mice, and that it increased Nr4a1-3 expression 
in WT mice, but not in Crtc1‒/‒ mice. However, it is worth noting that the relative gene 
expression levels of vehicle-injected Crtc1‒/‒ mice (Fig. 5, black bars) displayed several 
discrepancies, mostly in the HIP, as compared with those of mice that were exposed to the 
same behavioral paradigms, but not chronically injected (Fig. 2, black bars). The most striking 
difference was the surprising increased Bdnf expression in the HIP of vehicle-injected Crtc1‒/‒ 
mice (Fig. 5B). In addition, contrary to our previous observations and the results of Fig. 2, Nr4a1 
and Nr4a2 levels were not reduced in the HIP of Crtc1‒/‒ mice. These inconsistencies prompted 
us to compare the expression levels of Bdnf, BdnfIV, and Nr4a1-3 in WT and Crtc1‒/‒ mice 
control groups of Figures 2 and 5 (supplementary Fig. S1). The apparent increase of Bdnf 
expression in the HIP of vehicle-injected Crtc1‒/‒ mice (Fig. 5B) appeared to be rather due to a 
decreased Bdnf expression in chronically injected WT mice (Fig. S1A). Similarly, hippocampal 
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Nr4a1-3 levels seemed to be reduced mostly in WT mice chronically injected with vehicle (Fig. 
S1C-E). With a few exceptions, Crtc1‒/‒ mice appeared to be less affected by this chronic 
injection stress, which might explain the inconsistent data of Figure 5. In conclusion, the 
behavioral effect of chronic SAHA administration in Crtc1‒/‒ mice might be related to the 
restoration of normal Bdnf and BdnfIV expression in the PFC. However, unlike its effect in WT 
mice, chronic SAHA was not able to induce Nr4a1-3 expression in Crtc1‒/‒ mice, which suggests 
that the upregulation of these genes is not required to improve the behavioral despair of these 
animals in the OSFS paradigm. 
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4. Discussion 
The generation and characterization of Crtc1‒/‒ mice highlighted a key role of CRTC1 as a 
mediator of neuroplasticity-related genes expression potentially involved in the 
pathophysiology of mood disorders (Breuillaud et al., 2012). Moreover, we showed that CRTC1 
is required for proper behavioral response to chronic fluoxetine treatment. In the present 
study, we further investigated the role of CRTC1 in behavioral and molecular response to 
antidepressants. We were first interested to assess the effect of another class of 
antidepressants. The tricyclic antidepressant desipramine was selected as this type of 
compounds mainly acts on the noradrenergic system, while fluoxetine is a selective serotonin 
reuptake inhibitor. We observed that Crtc1‒/‒ mice responded similarly to desipramine and 
fluoxetine; i.e. desipramine had no effect on these animals in the OSFS protocol, whereas it had 
anxiolytic effects in the NIH paradigm. These results further suggest that CRTC1 is involved in 
behavioral response to antidepressants, mainly in behavioral despair-related paradigms, and 
that both noradrenergic and serotonergic pathways activated by antidepressants converge on 
CRTC1. We also observed that desipramine induced the expression of Crtc1 in the PFC of WT 
mice, which strengthens the hypothesis of a pivotal role of CRTC1 in antidepressant response.  
Interestingly, desipramine, like fluoxetine in our previous study, still elicited behavioral 
response in Crtc1‒/‒ mice in the NIH paradigm. This test has the advantage to be sensitive to 
chronic, but not acute antidepressant treatment. However, hyponeophagic behavior can be 
related to depressive but also anxious behavior (Dulawa and Hen, 2005) and both fluoxetine 
and desipramine have anxiolytic effects (Zohar and Westenberg, 2000). Therefore, the 
behavioral response of Crtc1‒/‒ mice observed in the NIH might be due to the anxiolytic effects 
of these treatments. The fact that these drugs still have anxiolytic effect in the absence of 
CRTC1 suggests that these effects are either CRTC1-independent, or that alternative pathways 
can be used to counteract the absence of CRTC1. 
Gene expression analyses revealed that desipramine induced the expression of Bdnf, BdnfIV, 
Nr4a1, and Nr4a2 in the HIP and PFC of WT mice, but failed to do so in Crtc1‒/‒ mice. While 
desipramine has been known for a long time to induce the expression of Bdnf (Nibuya et al., 
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1995), we report here that it also induces the expression of Nr4a1 and Nr4a2, which have been 
linked with mood disorders and Bdnf regulation (Buervenich et al., 2000; Volpicelli et al., 2007; 
Xing et al., 2006). Furthermore, we show that CRTC1 is required for the induction of Nr4a1 and 
Nr4a2 by chronic desipramine, thus suggesting a role for these nuclear receptors in the 
behavioral response to antidepressants. 
Considering this hypothesis, we attempted to counteract CRTC1 deletion and restore normal 
gene expression in Crtc1‒/‒ mice by treating them with a HDAC inhibitor. Epigenetic gene 
regulation has been widely shown to be involved in mood disorders. Mechanisms such as DNA 
methylation and histone acetylation (mechanisms that respectively repress and activate gene 
transcription) were found to be altered in depressed patients and in response to chronic stress 
(Sun et al., 2013; Vialou et al., 2013). Antidepressants also induce epigenetic changes, such as 
histone H3 hyperacetylation (Tsankova et al., 2006). HDAC inhibitors were found to have 
antidepressant effects in rodents, and to regulate a subset of genes in a similar way as 
antidepressants drugs (Covington et al., 2009; Schroeder et al., 2007; Uchida et al., 2011). Of 
particular interest for this study, Bdnf and Nr4a1-3 have been shown to be induced by HDAC 
inhibitors (Hawk et al., 2012; Schroeder et al., 2007; Vecsey et al., 2007). In the light of these 
results, we injected intraperitoneally the HDAC inhibitor SAHA to WT and Crtc1‒/‒ mice, and 
confirmed that a systemic administration of SAHA increased histone acetylation in the brain. 
Mutant mice responded to chronic SAHA in the OSFS paradigm, as their immobility time 
decreased over time, indicating a successful antidepressant effect of SAHA in these animals. 
However, the effect was not complete, as treated Crtc1‒/‒ mice did not reach the level of WT 
animals. This suggests that SAHA was not able to completely rescue the depressive-like 
behavior of these animals. It is important to keep in mind that Crtc1‒/‒ mice are complete 
knock-out animal, therefore developmental effects of CRTC1 deficiency cannot be excluded. 
Thus, some behavioral and molecular impairment might not be completely reversible, and 
might explain the partial behavioral effects of SAHA. Nevertheless, this result indicates that the 
depressive-like behavior of Crtc1‒/‒ mice can be partially rescued by acting at the epigenetic 
level. 
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In the NIH, the effect of SAHA was less clear. While it reduced the latency of WT mice, it only 
produced a trend to a decreased latency in Crtc1‒/‒ mice. However, basal latency of vehicle-
treated WT animals was abnormally high, which might indicate that the animals had higher 
basal anxiety, as compared with the NIH experiment of Fig. 1C. This might be explained by a 
possible effect of the three-week stressful OSFS procedure combined with chronic injections. 
All in all, NIH results suggest that SAHA had no effect on the anxiety of Crtc1‒/‒ mice, yet as WT 
animals seemed to present unusual higher anxiety, results of this test should be taken with 
caution. 
Molecular investigation of SAHA effects allowed us to better understand the behavioral effects 
of this treatment on Crtc1‒/‒ mice. In the PFC, the decreased Bdnf and BdnfIV expression was 
successfully rescued by SAHA treatment. This rescue of Bdnf expression may be related to the 
decreased immobility of Crtc1‒/‒ mice in the OSFS, as BDNF alterations have often been linked 
with behavioral despair (Borsoi et al., 2014; Koponen et al., 2005; Shirayama et al., 2002; 
Siuciak et al., 1997). While no effect of SAHA was observed in the HIP, Crtc1‒/‒ mice elusively 
displayed higher Bdnf expression in this structure, instead of their usual lower levels. The 
comparison of Bdnf levels in control groups of WT and Crtc1‒/‒ mice of Figure 2 and 5 suggested 
that the stress generated by chronic daily vehicle injections decreased Bdnf expression only in 
WT and not in Crtc1‒/‒ mice (Fig. S1). While it is generally suggested that acute and chronic 
stress decrease Bdnf expression (Duman and Monteggia, 2006), several studies have shown 
opposite findings (Charrier et al., 2006; Marmigere et al., 2003; Nair et al., 2007), thus revealing 
a complex interplay between stress and BDNF. Crtc1‒/‒ mice might thus present an altered 
reactivity to stress, evidenced by differential Bdnf regulation. This highlights again the 
importance of CRTC1 in the regulation of Bdnf and stress response, and should be a focus for 
future investigations. 
Interestingly, SAHA was found to increase Nr4a1-3 expression in the HIP and/or PFC of WT 
mice, which could be correlated with its antidepressant effect in these mice. This is in line with 
previous studies showing that HDAC inhibitors increase Nr4a1-3 expression via the CREB-CBP 
pathway, which is a key mechanism for memory enhancement (Hawk et al., 2012; Vecsey et al., 
2007). However, SAHA treatment was not able to increase Nr4a1-3 expression in Crtc1‒/‒ mice, 
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and therefore these genes are apparently not involved in the partial rescue of their depressive-
like behavior. These results suggest that CRTC1 is required for the CREB-CBP-mediated Nr4a1-3 
transcription induced by HDAC inhibitors. As this pathway is involved in learning processes, 
these findings are in keeping with the recently characterized important role of CRTC1 in 
memory and cognitive behavior (Nonaka et al., 2014a; Nonaka et al., 2014b; Parra-Damas et al., 
2014). Further characterization of cognitive and learning behaviors of Crtc1‒/‒ mice should 
better characterize CRTC1 function in these processes. 
 
5. Conclusions 
In this study, we provide evidence that CRTC1 is a key regulator of behavioral and molecular 
response to antidepressant. We show that CRTC1 is required for complete behavioral 
antidepressant response and for desipramine-induced expression of Bdnf and Nr4a1-2. By 
acting downstream of CRTC1, the HDAC inhibitor SAHA improves the depressive-like behavior 
of Crtc1‒/‒ mice. This partial rescue was paralleled by a restoration of Bdnf expression in the 
PFC, whereas SAHA was unable to increase Nr4a1-3 expression in these mice, thus suggesting 
that these orphan nuclear receptors do not play a major role in the improvement of their 
depressive-like behavior. In conclusion, several lines of evidence strongly suggest that CRTC1-
deficient mice are a valuable animal model of depressive phenotypes and treatment resistance. 
As an important regulatory mediator of depression-related genes, CRTC1 provide a new focus 
for future research aiming at a better understanding of depression and new therapeutic 
approaches. 
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Figure Legends 
 
Fig. 1.  Behavioral response of Crtc1‒/‒ mice to desipramine. (A) Experimental design and 
timeline. The OSFS protocol started when mice reached the age of 8 weeks. Mice underwent 
forced swimming session during the first four days (day -4 to -1). On day 0, desipramine 
treatment started and continued until the end of the experiment. Swimming session were 
regularly repeated until day 24. The NIH test was then applied from day 24 until day 27. On day 
28, animals were sacrificed. (B) Effects of chronic desipramine in the OSFS model of depression 
on Crtc1‒/‒ mice and WT littermates. During the four consecutive daily swimming sessions prior 
to treatment (Days -4 to -1), all groups increased their immobility time. Crtc1‒/‒ mice were 
significantly more immobile than WT mice during the two last sessions (+p<0.05, +++p<0.001 vs. 
WT untreated). From day 0 to day 23, WT and Crtc1‒/‒ mice received either water (n=7 and 
n=11 respectively) or chronic desipramine treatment (20 mg/kg in drinking water, n=8 and n=11 
respectively). Crtc1‒/‒ mice were significantly more immobile than WT mice, regardless of the 
treatment, during the whole procedure (+++p<0.001, vs. WT untreated). Desipramine-treated 
WT mice showed a progressive decrease in immobility time starting from day 9 of treatment 
(§p<0.05, §§p<0.01, §§§p<0.001, vs. themselves on day 2). Their immobility time was also 
significantly lower that untreated WT mice (*p<0.05, **p<0.01, vs. WT untreated). No effect of 
desipramine was seen in Crtc1‒/‒ mice. (C) Effects of chronic desipramine on the NIH paradigm 
in Crtc1‒/‒ and WT mice. Latencies to drink sweetened condensed milk are shown in the 
homecage and in the novel environment. Two mice were removed for having latency scores > 2 
SD from the mean. One mouse was removed for never having drunk the milk during the 
habituation and test phases. No significant difference of latency between the different groups 
was observed in the homecage conditions. In the novel environment, desipramine-treated WT 
mice (n=7) showed a non-significant trend to a decreased latency as compared to untreated WT 
mice (n=6). Desipramine significantly reduced the latency of Crtc1‒/‒ mice (n=10) compared to 
untreated Crtc1‒/‒ mice (n=11) (##p<0.05 vs. Crtc1‒/‒ mice). Data are mean ±SEM. 
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Fig. 2.  Molecular effects of desipramine in the HIP and PFC of Crtc1‒/‒ mice and WT littermates. 
(A) Desipramine had no effect on Crtc1 expression in the HIP of WT mice. In the PFC, WT mice 
treated with desipramine (n=8) showed increased levels of Crtc1 expression as compared to 
untreated WT mice (n=6) (*p<0.05 ,vs. WT untreated). (B) Untreated Crtc1‒/‒ mice (n=8) 
displayed lower hippocampal Bdnf expression compared to WT mice (n=7) (+p<0.05, vs. WT 
untreated). Desipramine had no effect on Bdnf expression of WT and Crtc1‒/‒ mice (n=8 and 
n=9 respectively). In the PFC, desipramine significantly increased Bdnf levels of WT mice 
(*p<0.01 vs. WT untreated) but not Crtc1‒/‒ mice. (C) Hippocampal BdnfIV expression was 
increased in desipramine-treated WT mice (**p<0.01, vs. WT untreated), but not in Crtc1‒/‒ 
mice. In the PFC, desipramine did not have a significant effect on both genotypes. (D-F) Effects 
of desipramine on the expression of Nr4a1-3. (D) Crtc1‒/‒ mice displayed lower levels of Nr4a1 
expression than WT mice in the HIP and PFC (+p<0.05, ++p<0.01, vs. WT untreated). Desipramine 
increased Nr4a1 levels of WT mice in the PFC but had no effect in the HIP (*p<0.05, vs. WT 
untreated). (E) Nr4a2 expression was found to be lower in the HIP and PFC of Crtc1‒/‒ mice 
compared to WT mice (+p<0.05, ++p<0.01, vs. WT untreated). Desipramine had no effect on 
Nr4a2 expression in Crtc1‒/‒ mice but increased its expression in the PFC of WT mice (*p<0.05, 
vs. WT untreated). (F) Desipramine increased Nr4a3 expression in the HIP of WT animal but had 
no effect on Crtc1‒/‒ mice (*p<0.05, vs. WT untreated). Crtc1‒/‒ mice displayed lower Nr4a3 
expression than WT animals in the PFC (+p<0.05, vs. WT untreated). Data are mean ±SEM. 
 
Fig. 3.  Expression of Hdac1,2,3,4,5,7,9 and effects of SAHA in the HIP and PFC of Crtc1‒/‒ and 
WT mice. (A) Hippocampal mRNA expression of most Hdac class I (1,2,3) and IIa (4,5,7,9) was 
unchanged in Crtc1‒/‒ mice (n=6) with the exception of Hdac9 which was upregulated as 
compared to WT mice (n=6) (**p<0.01, vs. WT mice). (B) No difference of Hdac expression in 
the PFC of Crtc1‒/‒ mice. (C-F) Histone H3 and H4 acetylation 2h after a single SAHA injection 
(25 mg/kg) in Crtc1‒/‒ and WT mice. Immunoblot analysis of acetylated histones H3 and H4 
(acetyl-H3 and acetyl-H4) and total H3 and H4 revealed single bands at the expected sizes of 15 
kDa and 10kDa, respectively. Panel (C) shows a representative western blot for acetylated 
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histone H3 (Acetyl-H3) and total histone H3 (total H3) in the HIP and PFC of WT and Crtc1‒/‒ 
mice. (D) SAHA-treated WT mice (n=5) presented higher levels of acetyl-H3 than vehicle-treated 
WT mice (n=5) in the hippocampus (*p<0.05, vs. WT Vehicle) and PFC (**p<0.01, vs. WT 
vehicle). SAHA-treated Crtc1‒/‒ mice (n=4) also presented increased histone H3 acetylation 
compared to vehicle-treated Crtc1‒/‒ mice (n=4) in the HIP and PFC (# p<0.05, vs. Crtc1‒/‒ 
Vehicle). Panel (E) shows a representative western blot for acetylated histone H4 (Acetyl-H4) 
and total histone H4 (total H4) in the HIP and PFC of WT and Crtc1‒/‒ mice. (F) SAHA-treated WT 
mice (n=4) presented a non-significant tendency to higher levels of acetyl-H4 than vehicle-
treated WT mice (n=5) in the HIP. In the PFC, SAHA increased levels of H4 acetylation in WT 
mice (**p<0.01, vs. WT Vehicle). SAHA-treated Crtc1‒/‒ mice (n=4) presented increased histone 
H4 acetylation compared to vehicle-treated Crtc1‒/‒ mice (n=4) in the HIP and PFC (# p>0.05, ## 
p<0.01, vs. Crtc1‒/‒ Vehicle). Data are mean ±SEM. 
 
Fig. 4.  Behavioral response of Crtc1‒/‒ mice to SAHA. (A) Experimental design and timeline. The 
OSFS protocol started when mice reached the age of 8 weeks. Mice underwent forced 
swimming session during the first four days (day -4 to -1). On day 0, SAHA treatment started 
and continued until the end of the experiment (last injection on day 27). Swimming session 
were regularly repeated until day 24. The NIH test was then applied from day 24 until day 27. 
On day 28, animals were sacrificed. (B) Effects of chronic SAHA in the OSFS model of depression 
on Crtc1‒/‒ mice and WT littermates. All groups increased their immobility time during the pre-
treatment period (Day -4 to day -1). Crtc1‒/‒ mice presented higher immobility time than WT 
mice starting from day -2 (+p<0.05, +++p<0.001, vs. WT mice). From day 0 until day 23, WT and 
Crtc1‒/‒ mice were daily injected i.p. with either vehicle (n=9 and n=8 respectively) or 25 mg/kg 
SAHA (n=9 and n=8 respectively). Vehicle-treated Crtc1‒/‒ mice were significantly more 
immobile that vehicle-treated WT mice during the whole procedure (+++p<0.001, vs. WT 
Vehicle). SAHA-treated WT mice significantly decreased their immobility time starting from day 
2 of treatment (§§p<0.01, §§§p<0.001, vs. themselves on day 2). Their immobility time was also 
significantly lower than vehicle-treated WT mice during the last three sessions (*p<0.05, vs. WT 
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Vehicle). SAHA-treated Crtc1‒/‒ mice significantly decreased their immobility time starting from 
day 12 of treatment (##p<0.01, vs. themselves on day 2). (C) Effects of chronic SAHA on the NIH 
paradigm. Latencies to drink sweetened condensed milk are shown in the homecage and in the 
novel environment. Two mice were removed for having latency scores > 2 SD from the mean. 
One mouse was removed for never having drunk the milk during the habituation and test 
phases. In the homecage conditions, no effect of SAHA was observed in any groups. In the novel 
environment, SAHA-treated mice (n=7) presented significant shorter latencies to drink the milk, 
as compared to vehicle-treated WT mice (n=8) (*p<0.05, vs. WT Vehicle). SAHA-treated Crtc1‒/‒ 
mice showed a non-significant trend to a shorter latency than vehicle-treated Crtc1‒/‒ mice (n=8 
for each group). Data are means ±SEM. 
 
Fig. 5.  Molecular effects of SAHA in the HIP and PFC of Crtc1‒/‒ mice and WT littermates. (A) 
SAHA had no effect on Crtc1 expression in the HIP and PFC of WT mice (n=8 for both group). (B) 
Untreated Crtc1‒/‒ mice (n=8) displayed higher hippocampal Bdnf expression compared to WT 
mice (+p<0.05, vs. WT mice). SAHA had no effect on Bdnf expression of WT and Crtc1‒/‒ mice 
(n=8 for each group). In the PFC, SAHA significantly increased Bdnf levels of Crtc1‒/‒ mice 
(##p<0.01 vs. Crtc1‒/‒ Vehicle). (C) Hippocampal BdnfIV expression was unchanged among the 
different groups. In the PFC, vehicle-treated Crtc1‒/‒ mice showed a decreased expression of 
BdnfIV (+p<0.05, vs. WT Vehicle). SAHA treatment significantly restored BdnfIV expression in 
Crtc1‒/‒ mice (##p<0.01, vs. Crtc1‒/‒ mice Vehicle). (D-F) Effects of SAHA on the expression of 
Nr4a1-3. (D) Crtc1‒/‒ mice displayed lower levels of Nr4a1 expression than WT mice in the PFC 
(++p<0.01, vs. WT Vehicle). Desipramine increased Nr4a1 levels of WT mice in the HIP but had 
no effect in the PFC (**p<0.01, vs. WT Vehicle). (E) Nr4a2 expression was found to be lower in 
the PFC of Crtc1‒/‒ mice compared to WT mice (++p<0.01, vs. WT Vehicle). SAHA had no effect 
on Nr4a2 expression in Crtc1‒/‒ mice but increased its expression in the HIP and PFC of WT mice 
(*p<0.05, vs. WT Vehicle). (F) SAHA had no effect on Nr4a3 expression in the HIP of all groups. 
In the PFC, SAHA increased Nr4a3 expression of WT animal but had no effect on Crtc1‒/‒ mice 
(*p<0.05, vs. WT Vehicle). Data are mean ±SEM. 





 
 
Fig. S1  Effects on gene expression of chronic intraperitoneal injections of vehicle solution 
(controls of Figure 5) compared to uninjected WT and Crtc1‒/‒ mice (controls of Figure 2). (A) 
Effects of chronic injections on total Bdnf expression in the hippocampus (HIP) and prefrontal 
cortex (PFC). Chronic injections reduced Bdnf levels of WT in the HIP and PFC (**p<0.01, 
***p<0.001) and of Crtc1‒/‒ mice in the PFC (###p<0.001, vs. Crtc1‒/‒ mice). (B) Effects of chronic 
injections on BdnfIV expression in the HIP and PFC. Chronic injections had no effect on BdnfIV 
levels in the HIP. Injections significantly downregulated BdnfIV in the PFC of Crtc1‒/‒ mice 
(##p<0.01, vs. Crtc1‒/‒ mice), and they also presented lower BdnfIV levels than injected WT mice 
in the same structure (§p<0.05, vs. WT injected). (C-F) Effects of chronic injections on Nr4a1-3 
expression in the HIP and PFC. Chronic injections significantly decreased the expression of 
Nr4a1-3 in the HIP and of Nr4a2-3 in the PFC of WT mice (*p<0.05, ***p<0.001, vs. WT mice). 
Non-injected Crtc1‒/‒ mice presented lower Nr4a1-3 levels in the HIP and PFC than non-injected 
WT mice (+p<0.05, vs. WT mice), except for Nr4a3 in the HIP. Injected Crtc1‒/‒ mice also 
displayed lower levels of Nr4a1 and Nr4a2 in the PFC (§p<0.01, vs. WT injected). In Crtc1‒/‒ mice, 
chronic injections only reduced the levels of Nr4a3 in the HIP (###p<0.001). *: WT vs. WT 
injected, +: WT vs. Crtc1‒/‒, #: Crtc1‒/‒ vs. Crtc1‒/‒ injected, §: WT injected vs. Crtc1‒/‒ injected. 
 
